Core Viewpoint - Huaneng Pharmaceutical (300110.SZ) and its wholly-owned subsidiaries have successfully participated in the bidding for the "3+N" alliance procurement in the Beijing-Tianjin-Hebei region, securing contracts for several products [1] Group 1: Procurement Participation - The company and its subsidiaries actively engaged in the bidding process for the "3+N" alliance procurement, specifically for Western medicine and traditional Chinese medicine [1] - The procurement project number is LH-YD2025-1, indicating a structured approach to the bidding process [1] Group 2: Selected Products and Revenue Impact - The selected products include: - Mixed sugar electrolyte injection with projected sales of 823,200 yuan, accounting for 0.06% of the company's total revenue in 2024 [1] - Betahistine hydrochloride sodium injection with projected sales of 2,220,300 yuan, representing 0.16% of total revenue [1] - Hydroxyethyl starch 130/0.4 sodium chloride injection with projected sales of 9,995,400 yuan, making up 0.74% of total revenue [1] - The total projected sales revenue from these selected products for 2024 is 13,038,900 yuan, which constitutes 0.96% of the company's total revenue [1]

Core Viewpoint - Huarun Pharmaceutical (300110.SZ) and its wholly-owned subsidiaries have successfully participated in the bidding for the "3+N" alliance procurement in the Beijing-Tianjin-Hebei region, securing contracts for several products [1] Group 1: Procurement Participation - The company and its subsidiaries actively engaged in the bidding process for the "3+N" alliance procurement project (Project No: LH-YD2025-1) [1] - The Tianjin Pharmaceutical Procurement Center recently announced the selection results, confirming the company's products as winners in this procurement [1] Group 2: Selected Products and Revenue Impact - The selected products include: - Mixed sugar electrolyte injection with a projected sales revenue of 823,200 yuan for 2024, accounting for 0.06% of the company's total revenue [1] - Betahistine hydrochloride sodium injection with a projected sales revenue of 2,220,300 yuan for 2024, accounting for 0.16% of the company's total revenue [1] - Hydroxyethyl starch 130/0.4 sodium chloride injection with a projected sales revenue of 9,995,400 yuan for 2024, accounting for 0.74% of the company's total revenue [1] - The total projected sales revenue from these selected products for 2024 is 13,038,900 yuan, representing 0.96% of the company's total revenue [1]

Core Insights - Huarun Pharmaceutical and its subsidiaries have successfully participated in the bidding for the "3+N" alliance procurement in the Beijing-Tianjin-Hebei region, securing contracts for several products [1] Group 1: Company Performance - The selected products are expected to generate a total sales revenue of 13.0389 million yuan in 2024, accounting for 0.96% of the company's total revenue for the year [1] - The revenue breakdown for the selected products includes: - Mixed sugar electrolyte injection: 823,200 yuan (0.06% of total revenue) - Betahistine hydrochloride sodium injection: 2,220,300 yuan (0.16% of total revenue) - Hydroxyethyl starch 130/0.4 sodium chloride injection: 9,995,400 yuan (0.74% of total revenue) [1] Group 2: Product Details - The selected products and their specifications include: - Mixed sugar electrolyte injection (500ml) priced at 15.29 yuan per bag, used for hydration and electrolyte maintenance [2] - Betahistine hydrochloride sodium injection (0.02g) priced at 5.76 yuan per bottle, primarily for Meniere's disease and related conditions [2] - Hydroxyethyl starch 130/0.4 sodium chloride injection available in multiple specifications, priced between 3.56 and 6.05 yuan per bag, used for treating and preventing blood volume deficiency [2]

证券代码：300110 证券简称：华仁药业 公告编号：2025-064 中选企业 中选产品 适应症 规格 中选价格 采购区域 华仁药业股 份有限公司 混合糖电解 质注射液 不能口服给药或口服给药不能 充分摄取时，补充和维持水分及 电解质，并补给能量。 500ml 15.29 元/袋 北京、天 津、河北 等多个省 （自治 区、直辖 市） 广西裕源药 业有限公司 盐酸倍他司 汀氯化钠注 射液 主要用于美尼尔氏综合征，亦可 用于动脉硬化、缺血性脑血管疾 病及高血压所致体位性眩晕、耳 鸣。 500ml:盐酸倍 他司汀 0.02g 与氯化钠 4.5g 5.76 元/瓶 华仁药业（日 照）有限公司 羟乙基淀粉 130/0.4 氯化 钠注射液 治疗和预防血容量不足，急性等 容血液稀释（ANH）。 250ml-500ml， 共计 5 个规格 3.56-6.05 元 /袋 一、中选产品的基本情况 二、本次中选对公司的影响 本次中选产品 2024 年合计销售收入为 1303.89 万元，占公司 2024 年营业收 入总额的 0.96%。其中混合糖电解质注射液 2024 年销售收入 82.32 万元，占公 司 2024 年营业收入 ...

华仁药业股份有限公司董事会 二〇二五年九月二十九日 附件：简历 华仁药业股份有限公司 关于补选第八届董事会非独立董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载，误导性陈述或重大遗漏。 证券代码：300110 证券简称：华仁药业 公告编号：2025-062 华仁药业股份有限公司（以下简称"公司"）于 2025 年 9 月 29 日召开第八届董 事会第十一次（临时）会议，审议通过了《关于补选第八届董事会非独立董事的议 案》。经公司控股股东西安曲江天授大健康投资合伙企业（有限合伙）提名，并 经公司董事会提名委员会审核通过，公司董事会同意补选李健先生为公司第八届 董事会非独立董事候选人（李健先生简历详见附件），任期自公司股东会审议通过 之日起至第八届董事会任期届满之日止。该事项尚需提交公司 2025 年第二次临时 股东会审议。本次补选董事完成后，董事会中兼任公司高级管理人员以及由职工代 表担任的董事人数总计不超过公司董事总数的二分之一。 特此公告。 李健先生，1982 年 10 月出生，中国国籍，中共党员，无境外永久居留权， 医学博士，副主任医师。曾先后供职于总后勤部青藏兵站部、 ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-063 华仁药业股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载，误导性陈述或重大遗漏。 一、本次股东会召开的基本情况 1、股东会届次：2025 年第二次临时股东会 2、召集人：公司董事会 3、会议召开的合法、合规性：经公司第八届董事会第十一次（临时）会议 审议通过，决定召开 2025 年第二次临时股东会，召集程序符合有关法律法规、 规范性文件和《公司章程》的规定。 4、会议召开日期和时间： （1）现场会议的召开时间为：2025 年 10 月 15 日（星期三）14:00 （2）网络投票时间：2025 年 10 月 15 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 10 月 15 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 10 月 15 日上午 9:15 至下午 15:00 期间的任意时间。 5、会议的召开方式：本次股东会采取现场 ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-061 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载，误导性陈述或重大遗漏。 表决结果：赞成 8 票，反对 0 票，弃权 0 票，获得通过。 一、董事会会议召开情况 华仁药业股份有限公司（以下简称"公司"）第八届董事会第十一次（临时） 会议于 2025 年 9 月 29 日以现场和网络相结合形式召开。会议通知已于 2025 年 9 月 24 日以电子邮件方式发给各位董事。会议由代行董事长侯瑞鹏先生召集并主 持，应出席会议的董事 8 名，实际出席会议的董事 8 名。会议召开符合法律法规、 《公司法》及《公司章程》的规定。 二、董事会会议审议情况 全体与会董事经认真审议和表决，形成以下决议： （一）审议通过《关于补选第八届董事会非独立董事的议案》 经公司控股股东西安曲江天授大健康投资合伙企业（有限合伙）提名，并经 公司董事会提名委员会审核通过，公司董事会同意补选李健先生为公司第八届董 事会非独立董事候选人，任期自公司股东会审议通过之日起至第八届董事会任期 届满之日止。具体内容详见公司同日披露在中国证监会指定创业板信息披露网 ...

Core Viewpoint - The company and its wholly-owned subsidiaries have actively participated in the bidding for the "3+N" alliance volume-based procurement project in the Beijing-Tianjin-Hebei region, achieving success in securing contracts for several products [1] Group 1: Company Participation - The company, along with its wholly-owned subsidiary Guangxi Yuyuan Pharmaceutical Co., Ltd. and Huaren Pharmaceutical (Rizhao) Co., Ltd., has engaged in the bidding process for the volume-based procurement [1] - The project number for the procurement is LH-YD2025-1, indicating a structured approach to the bidding process [1] Group 2: Procurement Results - The Tianjin Pharmaceutical Procurement Center has recently announced the results of the procurement, confirming that the company's products have been selected [1] - The selected products include mixed sugar electrolyte injection, betahistine hydrochloride sodium chloride injection, and hydroxyethyl starch 130/0.4 sodium chloride injection [1]

Core Viewpoint - The company and its wholly-owned subsidiaries have actively participated in the bidding for the "3+N" alliance volume-based procurement project in the Beijing-Tianjin-Hebei region, achieving success in securing contracts for several products [1] Group 1: Company Participation - The company, along with its wholly-owned subsidiaries Guangxi Yuyuan Pharmaceutical Co., Ltd. and Huaren Pharmaceutical (Rizhao) Co., Ltd., has engaged in the bidding process for the volume-based procurement [1] - The project number for the procurement is LH-YD2025-1, indicating a structured approach to the bidding process [1] Group 2: Procurement Results - The Tianjin Pharmaceutical Procurement Center has recently announced the results of the procurement, confirming that the company's products have been selected [1] - The selected products include mixed sugar electrolyte injection, betahistine hydrochloride sodium chloride injection, and hydroxyethyl starch 130/0.4 sodium chloride injection [1]

Group 1 - On September 24, Huaren Pharmaceutical's stock rose by 1.88%, with a trading volume of 58.77 million yuan [1] - The financing data on the same day showed a financing purchase amount of 7.48 million yuan, a repayment of 6.17 million yuan, resulting in a net financing purchase of 1.31 million yuan [1] - As of September 24, the total balance of margin trading for Huaren Pharmaceutical was 261 million yuan, accounting for 6.79% of its market capitalization, indicating a high level compared to the past year [1] Group 2 - As of September 20, the number of shareholders for Huaren Pharmaceutical was 40,500, a decrease of 1.46% from the previous period [2] - The average circulating shares per person increased by 1.48% to 29,156 shares [2] - For the first half of 2025, Huaren Pharmaceutical reported a revenue of 624 million yuan, a year-on-year decrease of 19.13%, and a net profit attributable to shareholders of 37.33 million yuan, down 49.01% year-on-year [2] Group 3 - Since its A-share listing, Huaren Pharmaceutical has distributed a total of 294 million yuan in dividends [3] - In the last three years, the cumulative dividend payout amounted to 49.65 million yuan [3]